B
B.K. Ahmed Rasheed
Researcher at Duke University
Publications - 23
Citations - 15883
B.K. Ahmed Rasheed is an academic researcher from Duke University. The author has contributed to research in topics: Glioma & Loss of heterozygosity. The author has an hindex of 20, co-authored 23 publications receiving 14451 citations.
Papers
More filters
Journal ArticleDOI
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
D. Williams Parsons,Siân Jones,Xiaosong Zhang,Jimmy Lin,Rebecca J. Leary,Philipp Angenendt,Parminder Mankoo,Hannah Carter,I-Mei Siu,Gary L. Gallia,Alessandro Olivi,Roger E. McLendon,B.K. Ahmed Rasheed,Stephen T. Keir,Tatiana Nikolskaya,Yuri Nikolsky,Dana A. Busam,Hanna Tekleab,Luis A. Diaz,James Hartigan,Doug R. Smith,Robert L. Strausberg,Suely Kazue Nagahashi Marie,Sueli Mieko Oba Shinjo,Hai Yan,Gregory J. Riggins,Darell D. Bigner,Rachel Karchin,Nick Papadopoulos,Giovanni Parmigiani,Bert Vogelstein,Victor E. Velculescu,Kenneth W. Kinzler +32 more
TL;DR: Recurrent mutations in the active site of isocitrate dehydrogenase 1 (IDH1) occurred in a large fraction of young patients and in most patients with secondary GBMs and were associated with an increase in overall survival.
Journal ArticleDOI
IDH1 and IDH2 Mutations in Gliomas
Hai Yan,D. Williams Parsons,Genglin Jin,Roger E. McLendon,B.K. Ahmed Rasheed,Weishi Yuan,Ivan Kos,Ines Batinic-Haberle,Siân Jones,Gregory J. Riggins,Henry S. Friedman,Allan H. Friedman,David A. Reardon,James E. Herndon,Kenneth W. Kinzler,Victor E. Velculescu,Bert Vogelstein,Darell D. Bigner +17 more
TL;DR: Mutations of NADP(+)-dependent isocitrate dehydrogenases encoded by IDH1 and IDH2 occur in a majority of several types of malignant gliomas.
Journal ArticleDOI
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
Patrick J. Killela,Zachary J. Reitman,Yuchen Jiao,Chetan Bettegowda,Nishant Agrawal,Luis A. Diaz,Allan H. Friedman,Henry S. Friedman,Gary L. Gallia,Beppino C. Giovanella,Arthur P. Grollman,Tong-Chuan He,Yiping He,Ralph H. Hruban,George I. Jallo,Nils Mandahl,Alan K. Meeker,Fredrik Mertens,George J. Netto,B.K. Ahmed Rasheed,Gregory J. Riggins,Thomas A. Rosenquist,Mark Schiffman,Ie Ming Shih,Dan Theodorescu,Michael Torbenson,Victor E. Velculescu,Tian Li Wang,Nicolas Wentzensen,Laura D. Wood,Ming Zhang,Roger E. McLendon,Darell D. Bigner,Kenneth W. Kinzler,Bert Vogelstein,Nickolas Papadopoulos,Hai Yan +36 more
TL;DR: TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages and provide a biomarker that may be useful for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.
Journal ArticleDOI
Altered Telomeres in Tumors with ATRX and DAXX Mutations
Christopher M. Heaphy,Roeland F. de Wilde,Yuchen Jiao,Alison P. Klein,Barish H. Edil,Chanjuan Shi,Chetan Bettegowda,Fausto J. Rodriguez,Charles G. Eberhart,Sachidanand Hebbar,G. Johan A. Offerhaus,Roger E. McLendon,B.K. Ahmed Rasheed,Yiping He,Hai Yan,Darell D. Bigner,Sueli Mieko Oba-Shinjo,Suely Kazue Nagahashi Marie,Gregory J. Riggins,Kenneth W. Kinzler,Bert Vogelstein,Ralph H. Hruban,Anirban Maitra,Nickolas Papadopoulos,Alan K. Meeker +24 more
TL;DR: The data suggest that an alternative telomere maintenance function may operate in human tumors with alterations in the ATRX or DAXX genes, which are common in human pancreatic neuroendocrine tumors.
Journal ArticleDOI
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Jeremy N. Rich,David A. Reardon,Terry S. Peery,Jeannette M. Dowell,Jennifer A. Quinn,Kara Penne,Carol J. Wikstrand,Lauren B. Van Duyn,Janet Dancey,Roger E. McLendon,James C. Kao,Timothy T. Stenzel,B.K. Ahmed Rasheed,Sandra Tourt-Uhlig,James E. Herndon,James J. Vredenburgh,John H. Sampson,Allan H. Friedman,Darell D. Bigner,Henry S. Friedman +19 more
TL;DR: Gefitinib is well tolerated and has activity in patients with recurrent glioblastoma and further study of this agent at higher doses is warranted.